This study was designed to evaluate the effects and mechanism of
tormentic acid (PTA) on diabetes and
dyslipidemia in high-fat (HF)-fed mice. Feeding C57BL/6J mice with a HF diet for 12 weeks induced
type 2 diabetes and
hyperlipidemia. During the last 4 weeks, the mice were given orally PTA (at two dosages) or
rosiglitazone (Rosi) or water. In this study, the HF diet increased
glucose,
triglyceride,
insulin, and
leptin levels, whereas PTA effectively prevented these phenomena and ameliorated
insulin resistance. PTA reduced visceral fat mass and hepatic
triacylglycerol contents; moreover, PTA significantly decreased both the area of adipocytes and ballooning degeneration of hepatocytes. PTA caused increased skeletal muscular
AMP-activated protein kinase (AMPK) phosphorylation and Akt phosphorylation and
glucose transporter 4 (GLUT4)
proteins, but reduced the hepatic expressions of phosphenolpyruvate carboxykinase (PEPCK) and
glucose-6-phosphatase (G6 Pase) genes. PTA enhanced skeletal muscular Akt phosphorylation and increased
insulin sensitivity. PTA also enhanced phospho-AMPK in the liver. Therefore, it is possible that the activation of AMPK by PTA results in decreasing hepatic
glucose production while increasing skeletal muscular GLUT4 contents, thus contributing to attenuating the diabetic state. Moreover, PTA exhibits an
antihyperlipidemic effect by down-regulations of the hepatic
sterol regulatory
element binding protein-1c (SREBP-1c) and
apolipoprotein C-III (
apo C-III) and an increased
peroxisome proliferator activated receptor (
PPAR)-α expression, thus resulting in decreases in blood
triglycerides. These findings demonstrated that PTA was effective for the treatment of diabetes and
hyperlipidemia in HF-fed mice.